Get the Stockscreener App
67.20
1.27%
0.84
After Hours:
67.22
0.02
+0.03%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC Stock (AZN) Latest News
AstraZeneca asthma drug more effective during attack than steroids, study finds - Reuters.com
Daiwa Securities Group Inc. Has $4.32 Million Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study - Yahoo Finance
Failure of AstraZeneca’s AZD4041 a blow for non-opioid OUD treatments - Clinical Trials Arena
Stock Watch: Investors Baulk At AstraZeneca And Bayer Q3 Updates - Citeline
Principal Street Partners LLC Purchases 8,986 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Sanders Capital LLC Has $1.17 Billion Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Quantbot Technologies LP Makes New Investment in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Bank of Montreal Can Increases Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Harvest Fund Management Co. Ltd Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Cerity Partners LLC Has $15.54 Million Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca reports results from trial of combination therapy for prostate cancer - Clinical Trials Arena
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Thrivent Financial for Lutherans - MarketBeat
AstraZeneca PLC Announces Positive High-Level Results from the Capitello-281 Phase III Trial - Marketscreener.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLCAZN - PR Newswire
AstraZeneca reports positive Phase 3 results for Truqap in prostate cancer (NASDAQ:AZN) - Seeking Alpha
AstraZeneca PLC (NASDAQ:AZN) Focuses on Growth in the U.S.: Is It the Best Time to Invest In AZN? - Insider Monkey
AstraZeneca remains steady Monday, underperforms market - MarketWatch
AstraZeneca’s Truqap Hits In Prostate Cancer - Citeline
AstraZeneca reports progress in prostate cancer treatment - Investing.com India
AstraZeneca PLC (NASDAQ:AZN) Shares Bought by DRW Securities LLC - MarketBeat
Fisher Asset Management LLC Purchases 524,175 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
GCAR and AstraZeneca execute agreement to evaluate AZD1390 for glioblastoma - Clinical Trials Arena
Charles Schwab Investment Management Inc. Buys 8,830 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (AZN): Among the Most Promising Cancer Stocks According to Hedge Funds - MSN
AstraZeneca reports positive results from prostate cancer trial - ShareCast
AstraZeneca prostate cancer drug shows promising phase III results - Proactive Investors UK
Nwam LLC Buys Shares of 8,047 AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca (AZN): A Top Pick for Hedge Funds Due to Innovation and Rising Demand - Yahoo Finance
Raymond James Trust N.A. Sells 11,239 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Eagle Asset Management Inc. - MarketBeat
AstraZeneca PLC ADR outperforms competitors on strong trading day - MarketWatch
AstraZeneca rises Friday, outperforms market - MarketWatch
AstraZeneca (AZN) and Amgen (AMGN) Submit New Asthma Drug Application - GuruFocus.com
AstraZeneca’s Andexxa May Continue Dangling In Accelerated Approval After Mixed Advisory Panel - Citeline
AstraZeneca rises Thursday, outperforms market - MarketWatch
AstraZeneca, Merck Add Patent to Campaign on Lynparza Copies (1) - Bloomberg Law
AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety ConcernsAstraZeneca (NASDAQ:AZN) - Benzinga
CEO & Executive Director of AstraZeneca Picks Up 9.9% More Stock - Simply Wall St
We Think AstraZeneca's (LON:AZN) Healthy Earnings Might Be Conservative - Yahoo Finance
Primecap Management Co. CA Trims Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca upgraded to Neutral from Sell at UBS - Yahoo Finance
AstraZeneca price target lowered to EUR 140 from EUR 150 at Berenberg - Yahoo Finance
AstraZeneca Talks Up US Growth as China Problems Fester - MSN
astrazeneca non-executive director buys company shares By Investing.com - Investing.com Nigeria
How AstraZeneca Ruling Could Change Dosage Patent Claims - Law360
Claim Spotter: AstraZeneca calls in Fieldfisher over HQ fire - The Lawyer
AstraZeneca PLC ADR underperforms Wednesday when compared to competitors - MarketWatch
As AstraZeneca reaches a 52-week high, is this still a top UK stock to consider? - MSN
AstraZeneca PLC (NASDAQ:AZN) Q3 2024 Earnings Call Transcript - MSN
AstraZeneca falls Wednesday, underperforms market - MarketWatch
AstraZeneca, United Utilities, AFC Energy: What brokers said today, - Proactive Investors UK
AstraZeneca raised to neutral at UBS despite China headwinds - MSN
AstraZeneca stock raised to neutral at UBS (AZN:NASDAQ) - Seeking Alpha
This AstraZeneca Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
AstraZeneca Says Current, Former Executives Involved in China Probe - MSN
AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Jennison Associates LLC - MarketBeat
Howe & Rusling Inc. Decreases Stock Holdings in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US - Yahoo Finance
Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time - Pharmaceutical Technology
AstraZeneca Is No Longer a Sell for Any Analyst as UBS Upgrades - Yahoo Finance
AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Boosted by Pathstone Holdings LLC - MarketBeat
AstraZeneca upgraded by leading investment bank, but challenges remainhere's why - Proactive Investors USA
AstraZeneca: UBS is no longer a seller - Marketscreener.com
UBS Upgrades AstraZeneca PLCDepositary Receipt () (AZN) - MSN
AstraZeneca PLC (AZN) Stock Price, Trades & News - GuruFocus.com
AstraZeneca’s Andexxa Could Be Headed For Withdrawal After US FDA’s Negative Advisory Committee Preview - Citeline
AstraZeneca PLC ADR rises Tuesday, still underperforms market - MarketWatch
AstraZeneca rises Tuesday, outperforms market - MarketWatch
Trump-induced Pharma fears shouldn't be long-lived - Marketscreener.com
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):